





eNOS (Phospho-Ser633) mouse mAb

Catalog No BYmab-10476 Isotype IgG Reactivity Human; Mouse;Rat Applications WB Gene Name NOS3 Protein Name eNOS (Phospho-Ser633) Immunogen Synthesized peptide derived from human eNOS (Phospho-Ser633) Specificity This antibody detects endogenous levels of eNOS (Phospho-Ser633) at Human, Mouse, Rat Formulation Liquid in PBS containing 50% glycerol, and 0.131% sodium azide. Source Monoclonal, Mouse, IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell membrane, Membrane, caveola, Cytoplasm, cytoskeleton, Golgi appartus, specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Function catalytic activity; L-arginine + n NADPH + n H(+) + m O(2) = citrullin		
Reactivity Human; Mouse;Rat Applications WB Gene Name NOS3 Protein Name eNOS (Phospho-Ser633) Immunogen Synthesized peptide derived from human eNOS (Phospho-Ser633) Specificity This antibody detects endogenous levels of eNOS (Phospho-Ser633) at Human, Mouse,Rat Formulation Liquid in PBS containing 50% glycerol, and 0.131% sodium azide. Source Monoclonal, Mouse,IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell Pathway Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity-L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+), cofactor-Binds 1 FAD, cofactor-Binds 1 FMN, cofactor-Heme group, cofactor-Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme, enzyme regulation: Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSIP and NOSIRIN, function-Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a c@MP-mediates digalal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-indepth angiogenesis in coronary vessels and promotes blood clotting through the	Catalog No	BYmab-10476
Applications WB Gene Name NOS3 Protein Name eNOS (Phospho-Ser633) Immunogen Synthesized peptide derived from human eNOS (Phospho-Ser633) Specificity This antibody detects endogenous levels of eNOS (Phospho-Ser633) at Human, Mouse, Rat Formulation Liquid in PBS containing 50% glycerol, and 0.131% sodium azide. Source Monoclonal, Mouse, IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity 290% Storage Stability -20°C/1 year Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell Pathway Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+), cofactor:Binds 1 FAD, cofactor:Binds 1 FMN, cofactor:Heme group, cofactor: Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme, enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSIP and NOSITRIN, function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a CsMP-mediates dispalar transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-indgn through the	Isotype	IgG
Gene Name NOS3 Protein Name eNOS (Phospho-Ser633) Immunogen Synthesized peptide derived from human eNOS (Phospho-Ser633) Specificity This antibody detects endogenous levels of eNOS (Phospho-Ser633) at Human, Mouse, Rat Formulation Liquid in PBS containing 50% glycerol, and 0.131% sodium azide. Source Monoclonal, Mouse, IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell Pathway Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:Larginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+), cofactor: Binds 1 FAD., cofactor: Binds 1 FMM., cofactor: Heme group, cofactor: Tetrahydrobiopterin (BH4). May stabilize	Reactivity	Human; Mouse;Rat
Protein Name eNOS (Phospho-Ser633) Immunogen Synthesized peptide derived from human eNOS (Phospho-Ser633) Specificity This antibody detects endogenous levels of eNOS (Phospho-Ser633) at Human, Mouse,Rat Formulation Liquid in PBS containing 50% glycerol, and 0.131% sodium azide. Source Monoclonal, Mouse,IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+), cofactor:Binds 1 FAN), cofactor:Heme group, cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme, enzyme regulation:Situalated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN, function:	Applications	WB
Immunogen Synthesized peptide derived from human eNOS (Phospho-Ser633)	Gene Name	NOS3
Specificity This antibody detects endogenous levels of eNOS (Phospho-Ser633) at Human, Mouse, Rat Formulation Liquid in PBS containing 50% glycerol, and 0.131% sodium azide. Source Monoclonal, Mouse, IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+), cofactor:Binds 1 FAD, cofactor:Binds 1 FMN, cofactor:Heme group, cofactor:Tetrahydrobiopterin (B4H). May stablize the dimeric form of the enzyme, enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN, function:Produces nitro oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-	Protein Name	eNOS (Phospho-Ser633)
Formulation Liquid in PBS containing 50% glycerol, and 0.131% sodium azide. Source Monoclonal, Mouse,IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell Pathway Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+), cofactor:Binds 1 FAD, cofactor:Beme group, cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme, enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN, function:Produces nitric oxide (NO) which is in implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the	Immunogen	Synthesized peptide derived from human eNOS (Phospho-Ser633)
Source Monoclonal, Mouse, IgG Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+), cofactor:Binds 1 FAD, cofactor:Binds 1 FMN, cofactor:Heme groupcofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme, enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN. function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the	Specificity	This antibody detects endogenous levels of eNOS (Phospho-Ser633) at Human, Mouse,Rat
Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell Pathway Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+), cofactor:Binds 1 FAD., cofactor:Binds 1 FAN, cofactor:Heme group, cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme, enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN., function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced anglogenesis in coronary vessels and promotes blood clotting through the	Formulation	Liquid in PBS containing 50% glycerol, and 0.131% sodium azide.
affinity-chromatography using epitope-specific immunogen. Dilution WB 1:500-2000 Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell Pathway Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+), cofactor:Binds 1 FAD., cofactor:Binds 1 FMN., cofactor:Heme group., cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme, enzyme regulation:Stimulated by calcium/calmodullin. Inhibited by NOSIP and NOSTRIN, function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the	Source	Monoclonal, Mouse,IgG
Concentration 1 mg/ml Purity ≥90% Storage Stability -20°C/1 year Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+).,cofactor:Binds 1 FAD.,cofactor:Binds 1 FMN.,cofactor:Heme group.,cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme,enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN.,function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the	Purification	•
Purity ≥90% Storage Stability -20°C/1 year Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell Pathway Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+).,cofactor:Binds 1 FAD.,cofactor:Binds 1 FMN.,cofactor:Heme group.,cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme,enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN.,function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the	Dilution	WB 1:500-2000
Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell Pathway Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+), cofactor:Binds 1 FAD., cofactor:Binds 1 FMN., cofactor:Heme group., cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme., enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN., function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the	Concentration	1 mg/ml
Synonyms Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell Pathway Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+), cofactor:Binds 1 FAD., cofactor:Binds 1 FMN., cofactor:Heme group., cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme., enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN., function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the	Purity	≥90%
(EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII) Observed Band Cell Pathway Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+), cofactor:Binds 1 FAD., cofactor:Binds 1 FMN., cofactor:Heme group.,cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme.,enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN.,function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the	Storage Stability	-20°C/1 year
Cell Pathway Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Function catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+).,cofactor:Binds 1 FAD.,cofactor:Binds 1 FMN.,cofactor:Heme group.,cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme.,enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN.,function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the	Synonyms	
Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity. Tissue Specificity Platelets, placenta, liver and kidney. Catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+).,cofactor:Binds 1 FAD.,cofactor:Binds 1 FMN.,cofactor:Heme group.,cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme.,enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN.,function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the	Observed Band	
catalytic activity:L-arginine + n NADPH + n H(+) + m O(2) = citrulline + nitric oxide + n NADP(+).,cofactor:Binds 1 FAD.,cofactor:Binds 1 FMN.,cofactor:Heme group.,cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme.,enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN.,function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the	Cell Pathway	Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic
+ n NADP(+).,cofactor:Binds 1 FAD.,cofactor:Binds 1 FMN.,cofactor:Heme group.,cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme.,enzyme regulation:Stimulated by calcium/calmodulin. Inhibited by NOSIP and NOSTRIN.,function:Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the	Tissue Specificity	Platelets, placenta, liver and kidney.
	Function	+ n NADP(+).,cofactor:Binds 1 FAD.,cofactor:Binds 1 FMN.,cofactor:Heme group.,cofactor:Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the

Nanjing BYabscience technology Co.,Ltd

网址: www.njbybio.com 官方热线: 025-5229-8998 监督电话: 15950492658




国内优质抗体供应商 精准的 WB 检测服务 24H 在线服务,欢迎咨询



	entry,polymorphism:Variation in NOS3 seem to be associated with susceptibility to coronary spasm.,similarity:Belongs to the NOS family.,similarity:Contains 1 FAD-binding FR-type domain.,similarity:Contains 1 flavodoxin-like
Background	Nitric oxide is a reactive free radical which acts as a biologic mediator in several processes, including neurotransmission and antimicrobial and antitumoral activities. Nitric oxide is synthesized from L-arginine by nitric oxide synthases. Variations in this gene are associated with susceptibility to coronary spasm. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009],
matters needing attention	Avoid repeated freezing and thawing!
Usage suggestions	This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.

Products Images



Western Blot analysis of various cells using eNOS (Phospho-Ser633) mouse mAb

Nanjing BYabscience technology Co.,Ltd

网址: www.njbybio.com 官方热线: 025-5229-8998 监督电话: 15950492658